Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 142

1.

Model-based approach for methoxy polyethylene glycol-epoetin beta drug development in paediatric patients with anaemia of chronic kidney disease [142/999 characters (incl. spaces)].

Chanu P, Schaefer F, Warady BA, Schmitt CP, Reigner B, Schnetzler G, Meyer Reigner S, Eisner M, Weichert A, Frey N.

Br J Clin Pharmacol. 2019 Nov 26. doi: 10.1111/bcp.14186. [Epub ahead of print]

PMID:
31770451
2.

Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.

Chacón-Araya M, Rey-Rodríguez D, Rodríguez De León F, Ramos-Esquivel A, Sunning T.

J Med Econ. 2019 Aug;22(8):736-741. doi: 10.1080/13696998.2019.1600527. Epub 2019 Apr 12.

PMID:
30915883
3.

Long-term maintenance of hemoglobin levels in hemodialysis patients treated with bi-weekly epoetin beta pegol switched from darbepoetin alfa: a single-center, 12-month observational study in Japan.

Kawai T, Kusano Y, Yamada K, Ueda C, Kawai A, Masaki T.

J Artif Organs. 2019 Jun;22(2):146-153. doi: 10.1007/s10047-018-1080-z. Epub 2018 Nov 14.

PMID:
30426250
4.

Effect of achieved hemoglobin level on renal outcome in non-dialysis chronic kidney disease (CKD) patients receiving epoetin beta pegol: MIRcerA CLinical Evidence on Renal Survival in CKD patients with renal anemia (MIRACLE-CKD Study).

Hayashi T, Uemura Y, Kumagai M, Kimpara M, Kanno H, Ohashi Y; MIRACLE-CKD Study Group.

Clin Exp Nephrol. 2019 Mar;23(3):349-361. doi: 10.1007/s10157-018-1649-0. Epub 2018 Oct 5.

5.

Patterns of Erythropoiesis-Stimulating Agent Use in European Hemodialysis Patients: The Dialysis Outcomes and Practice Patterns Study.

Fuller DS, Robinson BM, Locatelli F, Pisoni RL.

Nephron. 2018;140(1):24-30. doi: 10.1159/000490202. Epub 2018 Jun 26.

6.

Detection of erythropoiesis-stimulating agents in a single dried blood spot.

Reverter-Branchat G, Ventura R, Ezzel Din M, Mateus J, Pedro C, Segura J.

Drug Test Anal. 2018 Oct;10(10):1496-1507. doi: 10.1002/dta.2418. Epub 2018 Jul 5.

PMID:
29877055
7.

Semi-mechanistic Pharmacokinetic/Pharmacodynamic model of three pegylated rHuEPO and ior®EPOCIM in New Zealand rabbits.

Reynaldo-Fernández G, Solozábal J, Amaro D, Fernández-Sánchez EM, Rodríguez-Vera L, Bermejo M, Mangas-Sanjuan V, Troconiz IF.

Eur J Pharm Sci. 2018 Jul 30;120:123-132. doi: 10.1016/j.ejps.2018.04.047. Epub 2018 May 2.

PMID:
29729414
9.

Epoetin beta pegol for treatment of anemia ameliorates deterioration of erythrocyte quality associated with chronic kidney disease.

Aizawa K, Kawasaki R, Tashiro Y, Shimonaka Y, Hirata M.

BMC Nephrol. 2018 Jan 27;19(1):19. doi: 10.1186/s12882-018-0818-4.

10.

Indexes of the erythropoietin level in the blood plasma of chronic heart failure patients with anemia.

Zahidova KK.

J Basic Clin Physiol Pharmacol. 2018 Jan 26;29(1):11-17. doi: 10.1515/jbcpp-2016-0102.

PMID:
29220885
11.

Efficacy and Long-Term Safety of C.E.R.A. Maintenance in Pediatric Hemodialysis Patients with Anemia of CKD.

Fischbach M, Wühl E, Reigner SCM, Morgan Z, Schaefer F.

Clin J Am Soc Nephrol. 2018 Jan 6;13(1):81-90. doi: 10.2215/CJN.03570417. Epub 2017 Nov 2. Erratum in: Clin J Am Soc Nephrol. 2019 Jun 7;14(6):907.

12.

Liquid chromatography - high resolution mass spectrometry-based metabolomic approach for the detection of Continuous Erythropoiesis Receptor Activator effects in horse doping control.

Joré C, Loup B, Garcia P, Paris AC, Popot MA, Audran M, Bonnaire Y, Varlet-Marie E, Bailly-Chouriberry L.

J Chromatogr A. 2017 Oct 27;1521:90-99. doi: 10.1016/j.chroma.2017.09.029. Epub 2017 Sep 14.

PMID:
28941809
13.

Continuous erythropoiesis receptor activator (CERA) for the anaemia of chronic kidney disease.

Saglimbene VM, Palmer SC, Ruospo M, Natale P, Craig JC, Strippoli GF.

Cochrane Database Syst Rev. 2017 Aug 7;8:CD009904. doi: 10.1002/14651858.CD009904.pub2. Review.

14.

Comparative efficacy and safety in ESA biosimilars vs. originators in adults with chronic kidney disease: a systematic review and meta-analysis.

Amato L, Addis A, Saulle R, Trotta F, Mitrova Z, Davoli M.

J Nephrol. 2018 Jun;31(3):321-332. doi: 10.1007/s40620-017-0419-5. Epub 2017 Jun 23.

PMID:
28646375
15.

Efficacy of C.E.R.A. in Routine Clinical Practice for Correction of Anaemia and Maintenance of the Haemoglobin Levels in CKD Patients not on Dialysis.

Promod PJ, Deshpande R, Mohanty NK, Kulkarni S, Shah HA, Ganju A, Kukreja A, Joshi S.

J Assoc Physicians India. 2017 Mar;65(3):52-57.

PMID:
28462544
16.

Influence of Erythropoiesis-Stimulating Agents on HbA1c and Fructosamine in Patients with Haemodialysis.

Rasche FM, Ebert T, Beckmann J, Busch V, Barinka F, Rasche WG, Lindner TH, Schneider JG, Schiekofer S.

Exp Clin Endocrinol Diabetes. 2017 Jun;125(6):384-391. doi: 10.1055/s-0042-124577. Epub 2017 Apr 13.

PMID:
28407666
17.

Targets for adapting intravenous iron dose in hemodialysis: a proof of concept study.

Peters NO, Jay N, Cridlig J, Rostoker G, Frimat L.

BMC Nephrol. 2017 Mar 20;18(1):97. doi: 10.1186/s12882-017-0513-x.

18.

The effect of frequency of C.E.R.A. administration on the contribution of dietary iron for erythropoiesis.

Matsuo-Tezuka Y, Noguchi-Sasaki M, Kurasawa M, Yorozu K, Shimonaka Y.

Int J Hematol. 2017 Jul;106(1):60-70. doi: 10.1007/s12185-017-2215-3. Epub 2017 Mar 14.

PMID:
28293818
19.
20.

Epoetin beta pegol ameliorates flow-mediated dilation with improving endothelial nitric oxide synthase coupling state in nonobese diabetic rats.

Serizawa K, Yogo K, Tashiro Y, Kawasaki R, Endo K, Shimonaka Y, Hirata M.

Cardiovasc Ther. 2017 Apr;35(2). doi: 10.1111/1755-5922.12250.

Supplemental Content

Loading ...
Support Center